• Je něco špatně v tomto záznamu ?

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

L. Linde, S. Georgiadis, LM. Ørnbjerg, SH. Rasmussen, B. Michelsen, J. Askling, D. Di Giuseppe, JK. Wallman, J. Závada, K. Pavelka, M. Bernardes, CO. Matos, B. Glintborg, AG. Loft, D. Nordström, L. Kuusalo, B. Möller, MJ. Nissen, C. Codreanu, C....

. 2024 ; 76 (11) : 1558-1565. [pub] 20240819

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, srovnávací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003731

Grantová podpora
Novartis Pharma AG and IQVIA

OBJECTIVE: Because 66/68 joint counts are not always performed in routine care, we aimed to determine which of the modified 28-joint disease activity index for psoriatic arthritis (DAPSA28) or 28-joint disease activity score with C-reactive protein (DAS28-CRP) should be preferred for monitoring disease activity in psoriatic arthritis (PsA) when the original DAPSA (66/68 joints) is not available. METHODS: Prospectively collected real-world data of European bionaive patients with PsA initiating a first tumor necrosis factor inhibitor were pooled. Remission and response status were evaluated at 6 months by remission (DAPSA ≤ 4, DAPSA28 ≤ 4, and DAS28-CRP < 2.6), response (75% improvement for DAPSA and DAPSA28), and combined EULAR good/moderate responses for DAS28-CRP. Logistic regression analyses on multiple imputed data were used to identify baseline predictors. RESULTS: Remission and response cohorts included 3,159 and 1,866 patients, respectively. The 6-month proportions achieving remission/response were DAPSA (27%/44%), DAPSA28 (28%/44%), and DAS28-CRP (59%/80%). Of 14 possible baseline predictors, 11 predicted both DAPSA and DAPSA28 remission (8 of which also predicted their response, indicated by "*"): longer disease duration*, male sex*, and higher CRP* were positive, whereas older age*, higher body mass index*, patient fatigue*, and global, physician global, health assessment questionnaire score*, and tender and swollen* joint counts were negative predictors. Eight and five of these predicted DAS28-CRP remission and response, respectively. CONCLUSION: In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003731
003      
CZ-PrNML
005      
20250206104643.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acr.25396 $2 doi
035    __
$a (PubMed)38926900
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Linde, Louise $u Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000308631352
245    10
$a Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries / $c L. Linde, S. Georgiadis, LM. Ørnbjerg, SH. Rasmussen, B. Michelsen, J. Askling, D. Di Giuseppe, JK. Wallman, J. Závada, K. Pavelka, M. Bernardes, CO. Matos, B. Glintborg, AG. Loft, D. Nordström, L. Kuusalo, B. Möller, MJ. Nissen, C. Codreanu, C. Mogosan, B. Gudbjornsson, TJ. Love, C. Akleylek, F. Iannone, TK. Kvien, Z. Rotar, I. Castrejon, GJ. Macfarlane, ML. Hetland, M. Østergaard
520    9_
$a OBJECTIVE: Because 66/68 joint counts are not always performed in routine care, we aimed to determine which of the modified 28-joint disease activity index for psoriatic arthritis (DAPSA28) or 28-joint disease activity score with C-reactive protein (DAS28-CRP) should be preferred for monitoring disease activity in psoriatic arthritis (PsA) when the original DAPSA (66/68 joints) is not available. METHODS: Prospectively collected real-world data of European bionaive patients with PsA initiating a first tumor necrosis factor inhibitor were pooled. Remission and response status were evaluated at 6 months by remission (DAPSA ≤ 4, DAPSA28 ≤ 4, and DAS28-CRP < 2.6), response (75% improvement for DAPSA and DAPSA28), and combined EULAR good/moderate responses for DAS28-CRP. Logistic regression analyses on multiple imputed data were used to identify baseline predictors. RESULTS: Remission and response cohorts included 3,159 and 1,866 patients, respectively. The 6-month proportions achieving remission/response were DAPSA (27%/44%), DAPSA28 (28%/44%), and DAS28-CRP (59%/80%). Of 14 possible baseline predictors, 11 predicted both DAPSA and DAPSA28 remission (8 of which also predicted their response, indicated by "*"): longer disease duration*, male sex*, and higher CRP* were positive, whereas older age*, higher body mass index*, patient fatigue*, and global, physician global, health assessment questionnaire score*, and tender and swollen* joint counts were negative predictors. Eight and five of these predicted DAS28-CRP remission and response, respectively. CONCLUSION: In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.
650    _2
$a lidé $7 D006801
650    12
$a psoriatická artritida $x farmakoterapie $x krev $7 D015535
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a dospělí $7 D000328
650    12
$a C-reaktivní protein $x analýza $7 D002097
650    12
$a indukce remise $7 D012074
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    _2
$a senioři $7 D000368
650    _2
$a TNF-alfa $x antagonisté a inhibitory $7 D014409
650    _2
$a biologické markery $x krev $7 D015415
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Georgiadis, Stylianos $u Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000334859457
700    1_
$a Ørnbjerg, Lykke M $u Rigshospitalet, Glostrup, Denmark
700    1_
$a Rasmussen, Simon H $u Rigshospitalet, Glostrup, Denmark
700    1_
$a Michelsen, Brigitte $u Rigshospitalet, Glostrup, Denmark, Diakonhjemmet Hospital, Oslo, Norway, and Sørlandet Sykehus HF, Kristiansand, Norway
700    1_
$a Askling, Johan $u Karolinksa Institutet, Stockholm, Sweden
700    1_
$a Di Giuseppe, Daniela $u Karolinksa Institutet, Stockholm, Sweden
700    1_
$a Wallman, Johan K $u Skåne University Hospital, Lund, Sweden $1 https://orcid.org/0000000249152924
700    1_
$a Závada, Jakub $u Institute of Rheumatology and Charles University First Faculty of Medicine, Prague, the Czech Republic
700    1_
$a Pavelka, Karel $u Institute of Rheumatology and Charles University First Faculty of Medicine, Prague, the Czech Republic $1 https://orcid.org/0000000319528422 $7 jn99240000847
700    1_
$a Bernardes, Miguel $u University of Porto and Centro Hospitalar Universitário de São João, Porto, Portugal
700    1_
$a Matos, Carolina O $u Hospital de Santa Maria and Centro Academico de Medicina de Lisboa, Lisbon, Portugal $1 https://orcid.org/000000021954912X
700    1_
$a Glintborg, Bente $u The DANBIO Registry, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000289318482
700    1_
$a Loft, Anne Gitte $u Aarhus University Hospital and Aarhus Universitet, Aarhus, Denmark $1 https://orcid.org/000000016374841X
700    1_
$a Nordström, Dan $u Helsinki University Central Hospital, Helsinki, Finland
700    1_
$a Kuusalo, Laura $u University of Turku and Turku University Hospital, Turku, Finland $1 https://orcid.org/0000000152388439
700    1_
$a Möller, Burkhard $u Inselspital University Hospital Bern, Bern, Switzerland $1 https://orcid.org/0000000187696167
700    1_
$a Nissen, Michael J $u Geneva University Hospitals, Geneva, Switzerland
700    1_
$a Codreanu, Catalin $u University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
700    1_
$a Mogosan, Corina $u University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
700    1_
$a Gudbjornsson, Bjorn $u Landspitali National University Hospital of Iceland and University of Iceland, Reykjavik, Iceland
700    1_
$a Love, Thorvardur Jon $u Landspitali National University Hospital of Iceland and University of Iceland, Reykjavik, Iceland
700    1_
$a Akleylek, Cansu $u TC Demiroglu Bilim University, Istanbul, Turkey
700    1_
$a Iannone, Florenzo $u University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
700    1_
$a Kvien, Tore K $u Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000284413093
700    1_
$a Rotar, Ziga $u University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia
700    1_
$a Castrejon, Isabel $u General University Hospital Gregorio Maranon and Complutense University of Madrid, Madrid, Spain $1 https://orcid.org/0000000318112417
700    1_
$a Macfarlane, Gary J $u University of Aberdeen, Aberdeen, Scotland $1 https://orcid.org/0000000323223314
700    1_
$a Hetland, Merete L $u Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark
700    1_
$a Østergaard, Mikkel $u Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark
773    0_
$w MED00172712 $t Arthritis care & research $x 2151-4658 $g Roč. 76, č. 11 (2024), s. 1558-1565
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38926900 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104639 $b ABA008
999    __
$a ok $b bmc $g 2263480 $s 1239738
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 76 $c 11 $d 1558-1565 $e 20240819 $i 2151-4658 $m Arthritis care & research $n Arthritis Care Res (Hoboken) $x MED00172712
GRA    __
$p Novartis Pharma AG and IQVIA
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace